FDA makes mail-order abortion pills permanent
The policy revision by the U.S. Food and Drug Administration (FDA) made permanent an April announcement that it would not enforce during the COVID-19 pandemic a requirement that a woman must appear in person to receive mifepristone, the first drug in a two-step process known as medical or chemical abortion. While mifepristone may still be dispensed in qualified health-care facilities, it also may be mailed or delivered to a woman by a certified pharmacy.
The unsurprising FDA action followed by barely two weeks Supreme Court oral arguments regarding a case that could result in the reversal of the 1973 Roe v. Wade decision that legalized abortion nationwide. If Roe were to be overturned, abortion policy would return to the states. Abortion providers reportedly are preparing for a post-Roe era in which women would increasingly be able to obtain medical/chemical abortions rather than surgical ones.